Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;9(1):17-40.
doi: 10.1007/s40121-020-00286-6. Epub 2020 Feb 18.

Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms

Janet Y Wu  1 , Pavithra Srinivas  2 , Jason M Pogue  3
Affiliations
Review

Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms

Janet Y Wu et al. Infect Dis Ther. 2020 Mar.

Abstract

Cefiderocol, formerly S-649266, is a first in its class, an injectable siderophore cephalosporin that combines a catechol-type siderophore and cephalosporin core with side chains similar to cefepime and ceftazidime. This structure and its unique mechanism of action confer enhanced stability against hydrolysis by many β-lactamases, including extended spectrum β-lactamases such as CTX-M, and carbapenemases such as KPC, NDM, VIM, IMP, OXA-23, OXA-48-like, OXA-51-like and OXA-58. Cefiderocol's spectrum of activity encompasses both lactose-fermenting and non-fermenting Gram-negative pathogens, including carbapenem-resistant Enterobacterales. Cefiderocol recently received US Food and Drug Administration approval for the treatment of complicated urinary tract infections, including pyelonephritis, and is currently being evaluated in phase III trials for nosocomial pneumonia and infections caused by carbapenem-resistant Gram-negative pathogens. The purpose of this article is to review existing data on the mechanism of action, microbiology, pharmacokinetics, pharmacodynamics, efficacy, and safety of cefiderocol to assist clinicians in determining its place in therapy.

Keywords: CRE; Cefiderocol; Cephalosporin; Siderophore.

PubMed Disclaimer

Conflict of interest statement

Jason M. Pogue has been a consultant for Shionogi & Co., Ltd (manufacturer of cefiderocol), Merck, and QPex. Janet Y. Wu and Pavithra Srinivas have nothing to disclose.

References

    1. Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States AC, 2013. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013.... Accessed: August 25th, 2019.
    1. Morrill HJ, Pogue JM, Kaye KS, LaPlante KL. Treatment options for carbapenem-resistant enterobacteriaceae infections. Open Forum Infect Dis. 2015;2(2):ofv050. doi: 10.1093/ofid/ofv050. - DOI - PMC - PubMed
    1. Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing enterobacteriaceae. Clin Microbiol Rev. 2018;31(2):e00079-17. doi: 10.1128/CMR.00079-17. - DOI - PMC - PubMed
    1. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. J Clin Microbiol. 2006;44(8):2974–2976. doi: 10.1128/JCM.01021-06. - DOI - PMC - PubMed
    1. Rodriguez-Martinez JM, Poirel L, Nordmann P. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53(11):4783–4788. doi: 10.1128/AAC.00574-09. - DOI - PMC - PubMed

LinkOut - more resources